Dystroglycan, which serves as a major extracellular matrix receptor in muscle and the central nervous system, requires extensive O-glycosylation to function. We identified a dystroglycan missense mutation (Thr192→Met) in a woman with limb-girdle muscular dystrophy and cognitive impairment. A mouse model harboring this mutation recapitulates the immunohistochemical and neuromuscular abnormalities observed in the patient. In vitro and in vivo studies showed that the mutation impairs the receptor function of dystroglycan in skeletal muscle and brain by inhibiting the post-translational modification, mediated by the glycosyltransferase LARGE, of the phosphorylated O-mannosyl glycans on α-dystroglycan that is required for high-affinity binding to laminin.
M uscular dystrophies are genetic diseases characterized by weakness and progressive degeneration of skeletal muscle. The transmembrane protein dystroglycan, which is ultimately cleaved into an α and a β component, is a key link between the cytoskeleton and extracellular-matrix proteins that bear laminin globular domains (e.g., laminin, agrin, and neurexin). 1,2 The mucin domain of α-dystroglycan is modified with numerous O-linked oligosaccharides that are essential for its normal function as an extracellular-matrix receptor in various tissues, including skeletal muscle and brain. 2,3 Hypoglycosylation of α-dystroglycan and a consequent reduction of α-dystroglycan binding to extracellularmatrix proteins are observed in patients with the Walker-Warburg syndrome, muscleeye-brain disease, Fukuyama-type congenital muscular dystrophy, congenital muscular dystrophy types 1C and 1D, and limb-girdle muscular dystrophy 2I. 2 To date, genes encoding six putative and known glycosyltransferases (POMT1, POMT2, POMGnT1, LARGE, FKTN, and FKRP) have been shown to be responsible for approximately 50% of cases of these diseases, which are collectively referred to as secondary dystroglycanopathies 4-11 and which often feature brain abnormalities as well as muscular dystrophy. Despite recent advances in our understanding of the molecular mechanisms underlying secondary dystroglycanopathies, it remains unclear whether dystroglycan is the only target of these enzymes or whether other substrates contribute to the pathogenesis of these diseases.
Dystroglycan is known to be modified with several classes of oligosaccharides: N-glycans, mucin-type O-glycans, and O-mannosyl glycans. 2 The O-mannosyl gly-cans are thought to be responsible for dystroglycan's ligand-binding activity because the POMT1-POMT2 protein complex catalyzes the transfer of mannose to serine or threonine residues by means of an O-linkage. 2 We recently reported that maturation of α-dystroglycan to its laminin-binding form requires a novel biosynthetic pathway involving phosphorylation on O-mannosyl glycans and that LARGE is crucial for further modification of phosphorylated O-mannosyl glycans on α-dystroglycan. 12 Here we report a missense mutation in the dystroglycan-encoding gene, DAG1, in a patient with limb-girdle muscular dystrophy and cognitive impairment. Our studies revealed that this substitution interferes with LARGE-dependent maturation of phosphorylated O-mannosyl glycans on α-dystroglycan and leads to the disease-causing defect of α-dystroglycan binding to laminin.
Me thods

Clinical Information
The patient initially received a diagnosis of limb-girdle muscular dystrophy with mental retardation. 13 Clinical data regarding this patient have been reported elsewhere. 14 (See also the Supplementary Appendix, available with the full text of this article at NEJM.org.) This study was approved by the institutional review board at Hacettepe University, and written informed consent was obtained from the patient's guardians.
Biochemical Analysis
Biochemical analyses, including Western blotting, laminin-binding assays, and protein pull-down assays, were carried out as previously described. 3, 15 (For details about the cell-culture and biochemical methods used, see the Supplementary Appendix.)
Mouse Model
Protocols for generating a knock-in mouse model harboring a mutation equivalent to that in our patient, as well as animal care and animal procedures, were approved by the University of Iowa Animal Care and Use Committee (see the Supplementary Appendix).
R e s u l t s
We studied a Turkish patient with a relatively mild form of muscular dystrophy accompanied by cognitive impairment (see Case 2 in Dinçer et al. 14 ) . Although immunofluorescence analysis showed that α-dystroglycan was hypoglycosylated in this patient, no mutation was found in genes previously implicated in the pathogenesis of secondary dystroglycanopathies. 14 Since the dystroglycanencoding gene, DAG1, is a plausible candidate gene, we investigated whether our patient harbored a causative mutation therein. Sequencing of the coding and noncoding regions of DAG1 revealed a homozygous C-to-T missense mutation at position c.575, causing substitution of a methionine for a threonine at amino acid residue 192 (T192→M) of the protein (Fig. 1A) . Both parents were heterozygous carriers of this mutated allele, and allele segregation in the family was consistent with recessive disease inheritance (Fig. 1B) . The mutated threonine residue is located in the α-dystroglycan N-terminal and is highly conserved across species (Fig. 1C) .
We first assessed the effect of the newly identified α-dystroglycan mutation in vitro, with respect to expression, post-translational processing, or both. To this end, we transiently expressed the full-length wild-type and T192→M dystroglycan proteins in dystroglycan-null myoblasts. Western blotting with an antibody that recognizes functionally glycosylated α-dystroglycan (IIH6) 3,15 revealed considerably lower immunoreactivity for T192→M than for wild-type dystroglycan when similar amounts of protein were expressed (Fig.  1D ). Biotinylation analysis revealed that the cellsurface expression of T192→M and wild-type dystroglycan was similar (Fig. 1A in the Supplementary Appendix). Thus, in myoblasts, the T192→M substitution affects neither protein localization nor protein stability, but it does impair posttranslational modification. A laminin-binding assay confirmed that the T192→M mutation considerably reduces the effectiveness of dystroglycan as a laminin receptor (Fig. 1D, and Fig. 1B and 1C in the Supplementary Appendix).
We next assessed the effect of the T192→M mutation on functional modification of α-dystroglycan in vivo by introducing a T190→M mutation (which corresponds to the human T192→M mutation) into the mouse Dag1 gene (Fig. 2 in the Supplementary Appendix). Histologic analysis revealed hallmarks of muscular dystrophy, such as centrally nucleated fibers, in the mutant mice ( Fig. 2A, and Fig. 3A and 4 in the Supplementary Appendix). Immunofluorescence and biochemical analyses showed that the mutated α-dystroglycan was expressed at the skeletalmuscle sarcolemma but that both ligand-binding activity and IIH6 reactivity at this location were considerably decreased (Fig. 2B , and Fig. 3B and 5 in the Supplementary Appendix). Analysis of the uptake in the diaphragm of the membrane-impermeable Evans blue dye revealed disruption of the skeletal-muscle sarcolemma in the T190→M mice after exercise (Fig. 2C) . The mutant mice also had marked impairment of exercise performance (e.g., reduced forelimb grip strength) (Fig. 2D) . Mice heterozygous for the T190→M mutation did not have obvious muscle defects at the histologic level, despite a slight reduction in functional glycosylation of α-dystroglycan (Fig. 4 and 6 in the Supplementary Appendix). Thus, the T190→M mutation caused skeletal-muscle abnormalities in mice that were consistent with those observed in our patient.
In addition to its role in skeletal muscle, dystroglycan is crucial for maintaining the structure and function of the brain and neuromuscular junctions. 3, [16] [17] [18] Western blot and laminin-overlay analyses revealed that laminin-binding activity was significantly diminished in the brains of mice with the T190→M mutation (Fig. 3A) . Morphologic analysis of the neuromuscular junctions revealed that the T190→M mutation interfered with their maturation; on staining of diaphragm samples with α-Bungarotoxin conjugated with Alexa Fluor 488 (Invitrogen), which tightly binds acetylcholine receptors, the neuromuscular junctions in wild-type animals formed the expected pretzellike structure, whereas those in the T190→M mice were round and immature ( Fig. 3B and 3C , and Fig. 7 in the Supplementary Appendix). Consistent with impaired neuromuscular-junction maturation was the observation that the mutant mice had marked deficiencies in assays of neuromuscular function -for example, a reduction in retention time on a rotating-rod device (Fig. 3D) . Furthermore, although no structural abnormality was evident in the brains of the T190→M mice (an observation that was consistent with the results on magnetic resonance imaging [MRI] of the patient's brain), these mice had abnormal hindlimb clasping, a phenotype common to mouse models featuring neurologic impairment (Fig. 8 in the Supplementary Appendix). Collectively, these results provide strong evidence that the mutation in the patient caused neurologic impairment as well as muscular dystrophy as a consequence of impaired α-dystroglycan post-translational modification. Dystroglycan is also expressed in cardiac muscle, where its function as an extracellular-matrix receptor is important for limiting activity-induced myocardial damage. 19 Given that some patients with mutations in FKTN and FKRP have dilated cardiomyopathy, 20,21 we analyzed cardiac tissue from T190→M mice. We observed no obvious signs of any pathological abnormality, such as fibrosis or uptake of Evans blue dye after exercise (Fig. 9 in the Supplementary Appendix). Moreover, in contrast to the observed effects in brain and skeletal muscle, laminin-binding activity was affected only minimally in the hearts of T190→M mice (Fig.  3A) . Thus, it appears that normal cardiac function is maintained in T190→M knock-in mice and that the effects of the mutation on functional modification of α-dystroglycan are tissue-dependent.
Mutations in LARGE have been identified in patients with the Walker-Warburg syndrome or congenital muscular dystrophy type 1C, as well as in mice with myodystrophy (Large myd ). 9,10, 22 We recently found that LARGE is essential for phosphorylated O-mannosyl glycans to mature into a form capable of binding laminin. 12 We investigated the glycosylation status of T190→M α-dystroglycan by subjecting the protein to treatment with cold aqueous hydrofluoric acid, which cleaves phosphoester linkages, and to inorganic metal-affinity chromatography, which captures monoester-linked phosphorylated compounds. Hydrofluoric acid treatment clearly reduced the molecular weight of T190→M α-dystroglycan, and the beads on chromatography failed to capture T190→M α-dystroglycan, although they readily bound α-dystroglycan in samples from Large myd animals ( Fig. 10 in the Supplementary Appendix). These results suggest that T190→M α-dystroglycan bears phosphorylated O-mannosyl glycans but that these moieties are not sufficiently mature to confer laminin-receptor function on α-dystroglycan.
Our findings suggest that the T192→M mutation affects LARGE-dependent modification of α-dystroglycan. A previous study showed that the dystroglycan N-terminal serves as a binding site for LARGE, an interaction that is essential for α-dystroglycan's laminin-binding activity. 15 An in silico model suggested that the side chain of the methionine residue could affect the protein surface structure 23 (Fig. 11A in the Supplementary Appendix); accordingly, we hypothesized that the T192→M mutation abrogates the dystroglycan-LARGE interaction owing to a conformational change in the dystroglycan N-terminal. A pulldown assay with Fc-tagged α-dystroglycan mutants showed that although the wild-type pro- Panel A shows immunofluorescence and histologic analyses of T190→M skeletal-muscle (iliopsoas) sections prepared when the animals were 21 weeks of age. Serial sections were stained with antibodies against glycosylated α-dystroglycan (IIH6), the α-dystroglycan core (CORE), and β-dystroglycan (β-DG). Histologic abnormalities in the sections were evaluated by means of hematoxylin and eosin (H and E) staining. White arrowheads indicate centrally nucleated fibers (scale bar, 50 μm). Panel B shows a representative biochemical analysis of wild-type (WT) and T190→M α-dystroglycan isolated from wheat-germ agglutinin-enriched homogenates of skeletal muscle. Both Western blotting and laminin-overlay assays were carried out. Functional modification of α-dystroglycan was impaired by the T190→M mutation in vivo, as shown by the dramatic reduction in IIH6 immunoreactivity and laminin binding in the absence of major differences in CORE and β-DG immunoreactivity. Panel C shows the uptake of Evans blue dye in the diaphragm after exercise in wildtype and T190→M mice at 8 weeks of age. Panel D shows the whole-mouse grip-strength measurements, in gram-force (g-F), for the T190→M mice and their wild-type littermates. The P value was obtained with the use of Student's t-test.
tein bound to LARGE, variants harboring the T192→M mutation did not ( Fig. 11B and 11C in the Supplementary Appendix). These findings support the notion that the T192→M mutation in dystroglycan dramatically impairs the interaction between α-dystroglycan and LARGE, leading to incomplete post-translational modification of α-dys troglycan.
Discussion
Although genes responsible for O-glycosylationdependent muscular dystrophy (i.e., dystroglycanopathy) have been identified, the molecular mechanisms whereby mutations therein lead to impaired skeletal-muscle and brain function remain elusive -in part because defects in dystro- Here we describe such a case, which represents a new disease class (i.e., primary dystroglycanopathy). The T192→M mutation in this case caused deficiencies in α-dystroglycan glycosylation and a marked reduction in α-dystroglycan's ability to bind extracellular-matrix components. Furthermore, our knock-in mouse model harboring the patient's mutation recapitulates the phenotype of secondary dystroglycanopathies in humans, supporting the view that dystroglycan is the main -and probably only -protein that is subject to the glycosylation abnormalities that cause muscular dystrophy.
Patients with dystroglycanopathy have a broad spectrum of disease phenotypes, with or without brain involvement. Limb-girdle muscular dystrophy with mental retardation was diagnosed in our patient according to the classification system established by Godfrey et al. 13 Biochemical findings from analyses of mouse T190→M show that laminin-binding activity is considerably reduced ( Fig. 1 and 2) , suggesting that residual glycosylation may account for the relatively mild Panel A shows functional modification of α-dystroglycan in the brain and heart of mice with the T190→M mutation. Antibody staining and laminin-overlay assays were performed on blots of wheat-germ agglutinin-enriched homogenates from the brain and heart of T190→M mice and their wild-type (WT) littermates. Panels B and C show defects in maturation of the neuromuscular junction (NMJ) in the T190→M mice. Panel B shows representative images of the NMJ in the diaphragm; specimens were stained, with α-Bungarotoxin labeled with Alexa Fluor 488 (scale bar, 10 μm). Panel C shows individual data (circles) and mean (±SE) values for the NMJ area in wild-type and T190→M mice. Panel D shows the mean (±SE) values of five rotating-rod trials performed to assess neurologic defects in the T190→M mice. The time that the mice remained on the rotating rod was significantly longer for the wild-type mice than for the T190→M mice (P<0.001 by one-way analysis of variance).
muscle phenotype, as compared with the findings in patients with other congenital muscular dystrophies. Our patient had severe cognitive impairment, yet MRI revealed no gross structural abnormality in the brain. 14 In more severe cases of human dystroglycanopathy, as well as in mice with a brain-specific Dag1 knockout, structural as well as functional brain abnormalities have been documented. 3-6,9,10,16 Thus, it may be that residual laminin binding by human T192→M dystroglycan is sufficient for the development of the cerebral layer but not for the establishment of normal synaptic physiology. It remains unclear how dystroglycan contributes to synaptic physiology; however, reports that synaptic components possessing laminin globular domains play a fundamental role in establishing and maintaining synaptic function 24,25 suggest that a reduction in the affinity of dystroglycan for synaptic proteins could be responsible for the neurologic phenotypes observed in the patient described here.
Our biochemical analyses show that the T192→M mutation impairs maturation of a specific modification of phosphorylated O-mannosyl glycans on α-dys tro glycan (Fig. 10 in the Supplementary Appendix). In the heart, T190→M α-dystroglycan maintains substantial lamininbinding activity despite a reduction in molecular weight consistent with that in skeletal muscle and brain ( Fig. 2 and 3A) , and this remaining activity may contribute to preserved cardiac function (Fig. 8 in the Supplementary Appendix) . The tissue variability in levels of α-dystroglycan's functional glycosylation remains unexplained, but there are several possible explanations (e.g., tissue-specific protein complexes might increase the affinity between dystroglycan and LARGE, or the enzymatic activity of LARGE might be enhanced in heart tissue). Further investigation will be required to delineate the tissue-specific mechanisms ensuring that phosphorylated O-mannosyl residues of α-dys tro glycan mature into lamininbinding glycans.
In conclusion, we found a pathogenic missense mutation in DAG1 that selectively impairs further modification of phosphorylated O-mannosyl glycans on α-dys troglycan, leading to neuromuscular abnormalities. Our findings constitute evidence for the inclusion of DAG1 in the list of genes whose mutations cause muscular dystrophy and cognitive impairment in humans. 
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SUPPLEMENTARY METHODS
Additional clinical information
Clinical data on this patient were reported previously 14 . Briefly, the onset of disease occurred at approximately three years of age, shortly after the patient started to walk.
Her initial difficulties were an unsteady gait and difficulty climbing stairs. She has mild calf enlargement and ankle contractures, as well as increased lumbar lordosis. The patient was independently ambulant, but only for short distances (25-30 meters) at 16 years of age. Her intellectual development has been slow: she said her first few words at 7 years of age, and she used only two-word sentences at 16 years of age. At age 16 her IQ was 50, and she was unable to count money and perform independent activities. The creatine kinase concentration at the age of 15 was 4133 U/L. Her cranial MRI was normal.
Cell culture
The dystroglycan -/-myoblast cell line was established as previously described 26 . Briefly, Dystroglycan flox/flox mice were crossed with H-2Kb-tsA58 transgenic mice 26, 27 , and limb muscles from E18.5 dystroglycan flox/flox ; H-2Kb-tsA58 embryos were dissociated with 0.2% trypsin and 0.01% DNase. Cells were resuspended in growth medium (DMEM, 1 mM glutamine, 4.5 mg/ml glucose, 10% FBS, 10% horse serum, 0.5% chick embryo extract (Sera Laboratories Inc.), and gentamycin), supplemented with 20 U/ml of recombinant mouse interferon-γ (Sigma-Aldrich, I4777, St. Louis, MO) and pre-plated for 20 min at 33°C. Non-adherent cells were transferred to a Matrigel-coated tissue culture dish (BD Falcon, San Jose, CA) and maintained in growth medium at 33°C/10% CO 2 . Dystroglycan flox/flox myoblasts that had been screened for their ability to differentiate into myotubes were infected with a pBabe-Cre retroviral vector, and dystroglycan -/-myoblasts were identified by PCR. TSA201, a transformed human kidney cell line stably expressing an SV40 T antigen, was cultured as previously described 15 .
Antibodies
The monoclonal antibody to the glycosylated form of α-dystroglycan (IIH6), as well as the polyclonal antibody to β-dystroglycan (βDG; ap83), that were used had been 
Vector construction
The T192M-dystroglycan mutation was introduced into expression vectors encoding rabbit dystroglycan, using a conventional PCR method. To generate adenoviral vectors expressing the T192M-dystroglycan mutant, we subcloned a full-length cDNA carrying the T192M mutation into the HindIII and NotI sites of the vector pAd5RSVK-NpA (obtained from the University of Iowa Gene Transfer Vector Core). Adenoviral vectors were generated as described elsewhere 15 . Construction of expression vectors encoding Fc2 (the dystroglycan N-terminus) or Fc5 (α-dystroglycan) were described elsewhere 15 .
Biochemical and ligand-binding analyses
Glycoprotein enrichment and Western blotting were performed as described previously, with minor modifications 3,15 .
For the cell-surface biotinylation assay, myoblasts infected by adenoviruses expressing WT-or T192M-dystroglycan were washed three times with ice-cold PBS (-) and incubated with PBS (-) containing the membrane impermeable sulfo-NHS-LC-biotin reagent (PIERCE, Rockford, IL) for one hour at 4°C. The cells were then washed twice at room temperature with PBS (-) containing 100 mM glycine, to quench the cross-linker and remove excess biotin. Cells were rinsed in PBS (-) and lysed in Buffer A (150 mM NaCl, 50 mM Tris, pH 7.5) plus 1% Triton X-100 containing a cocktail of protease inhibitors. Cell-surface proteins were immunoprecipitated from the biotin-labeled cells using ImmunoPure Immobilized Streptavidin (PIERCE, Rockford, IL). The samples were then analyzed by Western blotting with the IIH6, CORE, and βDG antibodies.
For the pull-down assay, fusion proteins encoding full-length α-dystroglycan and the α-dystroglycan N-terminus bearing the T192M mutation and attached to Fc (Fc5 and Fc2, respectively) were expressed independently in TSA201 cells and purified from the cell lysates using Protein-A affinity beads 15 . The affinity bead-DGFc fusion protein complexes were then incubated with lysates from TSA201 cells expressing myc-tagged LARGE 28 . Materials bound to the beads were eluted with Laemmli sample buffer and analyzed by Western blotting. Binding between dystroglycan and LARGE was detected using the Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE).
Ligand overlay and laminin solid-phase assays were performed as previously Confocal microscopy was performed images were analyzed using FV10 ver-1.5
(Olympus, Center Valley, PA). Data show the mean ± s.e.m. for three independent experiments.
Generation of the T190M-dystroglycan knock-in mice
Genomic fragments of the mouse Dag1 gene were isolated from a 129/Sv genomic library 30 . The nucleotide sequence encoding Thr-190 (GTC CTT ACA GTG ATT) was mutated to encode a methionine, and a CviAII restriction site was introduced simultaneously (sequence of the mutant allele: GTC CTC ATG GTG ATT; the methionine codon is shown in bold, and the CviAII site is underlined). The Neo cassette flanked by LoxP sites was inserted into a SalI site located between exon 2 and exon 3. A thymidine kinase cassette was attached to the 5' end of the vector for negative selection.
The NotI-linearized construct was electroporated into R1 ES cells, and cell clones resistant to positive and negative selection were screened by PCR over the 5' and 3' sides of the insertion. Positive ES clones were microinjected into C57BL/6J blastocysts to generate chimeric mice. PCR-based genotyping of each locus was carried out using the following primers: 5'-homologous recombination: #5742 (5'-CGTCCGCCCCTTTCTGTTCTGGTTACTC -3') and #5737 (5'-GCGGGGCTGCTAAAGCGCATGCTCCAGA -3'); 3'-homologous recombination:
#5856 (5'-CATCGCCTTCTATCGCCTTCTTGACGAGTT -3') and #5857 (5'-CTCTTCTGAGGCACATCTCCCATCACG -3'). To confirm that the T190M mutation was present in the Dag1 locus, we amplified the mutation-containing DNA fragment (426 bp) using the following primers: #5530 (5'-TGATGGTAACATTTATAACTCACAC-3') and #5531 (5'-GTTGTGAAGTTCTACTTCTGAGAAGCTC-3'). The resultant fragment was digested with CviAII (New England Labs, Ipswich, MA), yielding bands of
Analysis of the T190M-dystroglycan knock-in mice
Immunofluorescence analysis and hematoxylin-eosin staining were carried out as described previously 3 . For the fore-limb grip-strength test, T190M (n=10) and littermate control (WT; n=9) mice at 11-20 weeks of age were examined using a grip-strength meter knock-in mice and littermate controls were injected with EBD one day before exercise.
Those mice were subjected to downhill running on a treadmill with a built-in shock grid at a 15 degree declination. After a warm-up running (3 m/min, 5 minutes), the initial running speed of 10 m/min was increased every 5 minutes by 5 m/min until the maximal speed (25 m/min) was reached. Exhaustion was defined as the point at which the animal would not resume running. Tissues were harvested at one day after the exercise. In evaluating cardiac muscle pathology, we used skeletal and cardiac muscle-specific (MCK-cre) dystrolgycan-deficient mice 27 as a control. HFaq treatment and an IMAC bead binding assay were performed as described previously 12 . Rotarod performance was tested in T190M knock-in mice and littermates, 10 to 15 weeks of age, using the ROTOR-ROD system (San Diego Instruments, San Diego, CA). The mice were placed on top of the beam, and the rotarod accelerated gradually, without jerks, from 0 to 35 rpm over a two-minute trial. Latencies for the mice to fall from the rod were recorded automatically. Each mouse was subjected to 5 trials at 15-min intertrial intervals, on each of three consecutive days.
Molecular modeling
The N-terminal portion of the T192M mutant of α-dystroglycan was modeled using the SWISS-MODEL program for the analysis, and the crystal structure of the WT mouse Upper panels show H&E staining of cardiac sections from WT and T190M mice. Lower panels show Evans blue dye uptake (EBD, in Red) in the heart. Dystroglycan-null hearts were analyzed as negative controls 27 . EBD uptake was observed only in the dystroglycan-null hearts, suggesting that a deficiency in dystroglycan function causes susceptibility to exercise-induced cardiac membrane damage. White bar: 50 μm. 
